Aclinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum

A case report

Chiara De Divitiis, Claudia Von Arx, Roberto Carbone, Fabiana Tatangelo, Elena Di Girolamo, Giovanni Maria Romano, Alessandro Ottaiano, Elisabetta De Lutio Di Castelguidone, Rosario Vincenzo Iaffaioli, Salvatore Tafuto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.

Original languageEnglish
Pages (from-to)669-675
Number of pages7
JournalOncoTargets and Therapy
Volume8
DOIs
Publication statusPublished - Mar 31 2015

Fingerprint

Neuroendocrine Tumors
Somatostatin
Ileum
Neoplasms
Octreotide
Therapeutics
Tomography
Liver

Keywords

  • Metastatic tumor of the ileum
  • Neuroendocrine tumor
  • Octreotide
  • Radiological tumor response
  • Somatostatin analogs

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{8056365f687840499ca96a5762a6f766,
title = "Aclinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: A case report",
abstract = "Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.",
keywords = "Metastatic tumor of the ileum, Neuroendocrine tumor, Octreotide, Radiological tumor response, Somatostatin analogs",
author = "{De Divitiis}, Chiara and {Von Arx}, Claudia and Roberto Carbone and Fabiana Tatangelo and Girolamo, {Elena Di} and Romano, {Giovanni Maria} and Alessandro Ottaiano and {De Lutio Di Castelguidone}, Elisabetta and Iaffaioli, {Rosario Vincenzo} and Salvatore Tafuto",
year = "2015",
month = "3",
day = "31",
doi = "10.2147/OTT.S71025",
language = "English",
volume = "8",
pages = "669--675",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Aclinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum

T2 - A case report

AU - De Divitiis, Chiara

AU - Von Arx, Claudia

AU - Carbone, Roberto

AU - Tatangelo, Fabiana

AU - Girolamo, Elena Di

AU - Romano, Giovanni Maria

AU - Ottaiano, Alessandro

AU - De Lutio Di Castelguidone, Elisabetta

AU - Iaffaioli, Rosario Vincenzo

AU - Tafuto, Salvatore

PY - 2015/3/31

Y1 - 2015/3/31

N2 - Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.

AB - Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.

KW - Metastatic tumor of the ileum

KW - Neuroendocrine tumor

KW - Octreotide

KW - Radiological tumor response

KW - Somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=84929417083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929417083&partnerID=8YFLogxK

U2 - 10.2147/OTT.S71025

DO - 10.2147/OTT.S71025

M3 - Article

VL - 8

SP - 669

EP - 675

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -